Centene Corp Valuation – May 2018 $CNC

Company Profile (excerpt from Reuters): Centene Corporation, incorporated on September 26, 2001, is a healthcare company. The Company provides a portfolio of services to government sponsored healthcare programs, focusing on under-insured and uninsured individuals. The Company operates through two segments: Managed Care and Specialty Services. It provides member-focused services through locally based staff by assisting in accessing care, coordinating referrals to related health and social services and addressing member concerns and questions. It also provides education and outreach programs to inform and assist members in accessing appropriate healthcare services. The Managed Care segment consists of the Company’s health plans, including all of the functions needed to operate them. The Specialty Services segment consists of the Company’s specialty companies, offering auxiliary healthcare services and products.

CNC Chart

CNC data by YCharts


Downloadable PDF version of this valuation:

ModernGraham Valuation of CNC – May 2018

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

Defensive Investor; must pass 6 out of the following 7 tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $20,333,704,667 Pass
2. Sufficiently Strong Financial Condition Current Ratio > 2 1.01 Fail
3. Earnings Stability Positive EPS for 10 years prior Pass
4. Dividend Record Dividend Payments for 10 years prior Fail
5. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end 410.02% Pass
6. Moderate PEmg Ratio PEmg < 20 24.21 Fail
7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 2.74 Fail
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.
1. Sufficiently Strong Financial Condition Current Ratio > 1.5 1.01 Fail
2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 60.14 Fail
3. Earnings Stability Positive EPS for 5 years prior Pass
4. Dividend Record Currently Pays Dividend Fail
5. Earnings Growth EPSmg greater than 5 years ago Pass


Stage 2: Determination of Intrinsic Value

EPSmg $4.77
MG Growth Estimate 15.00%
MG Value $183.67
Opinion Undervalued
MG Grade C-
MG Value based on 3% Growth $69.17
MG Value based on 0% Growth $40.55
Market Implied Growth Rate 7.85%
Current Price $115.49
% of Intrinsic Value 62.88%

Centene Corp does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, poor dividend history, and the high PEmg and PB ratios. The Enterprising Investor has concerns regarding the level of debt relative to the current assets, and the lack of dividends. As a result, all value investors following the ModernGraham approach should explore other opportunities at this time or proceed cautiously with a speculative attitude.

As for a valuation, the company appears to be Undervalued after growing its EPSmg (normalized earnings) from $1.35 in 2014 to an estimated $4.77 for 2018. This level of demonstrated earnings growth outpaces the market’s implied estimate of 7.85% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on the Benjamin Graham value investing formula, returns an estimate of intrinsic value above the price.

At the time of valuation, further research into Centene Corp revealed the company was trading above its Graham Number of $78.3. The company does not pay a dividend. Its PEmg (price over earnings per share – ModernGraham) was 24.21, which was below the industry average of 42.49, which by some methods of valuation makes it one of the most undervalued stocks in its industry. Finally, the company was trading above its Net Current Asset Value (NCAV) of $-37.66.

Centene Corp receives an average overall rating in the ModernGraham grading system, scoring a C-.

Stage 3: Information for Further Research

Net Current Asset Value (NCAV) -$37.66
Graham Number $78.30
PEmg 24.21
Current Ratio 1.01
PB Ratio 2.74
Current Dividend $0.00
Dividend Yield 0.00%
Number of Consecutive Years of Dividend Growth 0

Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Balance Sheet Information 3/1/2018
Total Current Assets $10,976,000,000
Total Current Liabilities $10,890,000,000
Long-Term Debt $5,172,000,000
Total Assets $25,170,000,000
Intangible Assets $6,814,000,000
Total Liabilities $17,667,000,000
Shares Outstanding (Diluted Average) 177,690,000

Earnings Per Share History

EPS History
Next Fiscal Year Estimate $6.90
Dec2017 $4.69
Dec2016 $3.43
Dec2015 $2.88
Dec2014 $2.25
Dec2013 $1.47
Dec2012 $0.02
Dec2011 $1.06
Dec2010 $0.94
Dec2009 $0.95
Dec2008 $0.94
Dec2007 $0.82
Dec2006 -$0.51
Dec2005 $0.62
Dec2004 $0.51
Dec2003 $0.44
Dec2002 $0.37
Dec2001 $0.27
Dec2000 $0.19
Dec1999 -$1.83

Earnings Per Share – ModernGraham History

EPSmg History
Next Fiscal Year Estimate $4.77
Dec2017 $3.45
Dec2016 $2.56
Dec2015 $1.93
Dec2014 $1.35
Dec2013 $0.90
Dec2012 $0.67
Dec2011 $0.97
Dec2010 $0.83
Dec2009 $0.70
Dec2008 $0.55
Dec2007 $0.36
Dec2006 $0.18
Dec2005 $0.50
Dec2004 $0.41
Dec2003 $0.20
Dec2002 -$0.01

Recommended Reading:

Other ModernGraham posts about the company

Centene Corp Valuation – Initial Coverage $CNC

Other ModernGraham posts about related companies

Thermo Fisher Scientific Inc Valuation – April 2018 $TMO
Illumina Inc Valuation – April 2018 $ILMN
Waters Corp Valuation – April 2018 $WAT
Align Technology Inc Valuation – April 2018 $ALGN
HCA Healthcare Inc Valuation – April 2018 $HCA
Express Scripts Holding Co Valuation – April 2018 $ESRX
Stryker Corp Valuation – April 2018 $SYK
Cerner Corporation Valuation – April 2018 $CERN
Quest Diagnostics Inc Valuation – April 2018 $DGX
Laboratory Corporation of America Holdings Valuation – March 2018 $LH


The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.